Early Use of Steroid-Sparing Agents in the Inactivation of Moderate-to-Severe Active Thyroid eye Disease

A Step-Down Approach

Zuzana Sipkova; Elizabeth A. Insull; Joel David; Helen E. Turner; Shay Keren; Jonathan H. Norris


Clin Endocrinol. 2018;89(6):834-839. 

In This Article


Thyroid eye disease (TED) is an autoimmune disorder, although its pathogenesis is not completely understood which is reflected in the relatively limited therapeutic options. Our findings suggest that MTX is a well-tolerated, safe, and effective first-line SSA for moderate-to-severe active TED treatment, significantly reducing the total corticosteroid dose required.